Table 2.
Vitamin E |
Placebo |
|||||
---|---|---|---|---|---|---|
Histological feature | ALT R* (n = 34) | ALT NR* (n = 37) | P value | ALT R* (n = 11) | NR* (n = 57) | P value |
Mean change in steatosis score | −1.1 | −0.4 | <0.001 | −0.7 | −0.0 | <0.001 |
Mean change in inflammation score | −1.1 | −0.3 | <0.001 | −0.5 | −0.2 | 0.14 |
Mean change in Ballooning score | −0.8 | −0.2 | 0.01 | −0.5 | −0.2 | 0.42 |
Mean change in NAS† score | −3.0 | −0.8 | <0.001 | −1.6 | −0.4 | 0.03 |
Mean change in Fibrosis score | −0.5 | −0.2 | 0.34 | −0.8 | −0.0 | 0.04 |
Decrease in NAS by ≥2 points | 82% | 32% | <0.001 | 55% | 25% | 0.07 |
Resolution of NASH‡ | 44% | 22% | 0.07 | 45% | 14% | 0.03 |
Mean change in Weight (kg) | −0.9 | 1.8 | 0.03 | −3.7 | 1.8 | 0.01 |
ALT R = response defined as decrease to 40 U/L or less and by 30% or more from baseline. ALT NR = lack of ALT response.
Total non-alcoholic fatty liver activity score (NAS), comprising the sum of scores for steatosis, inflammation and ballooning cell injury.
Resolution of histological features that fulfil the criteria for diagnosis of non-alcoholic steatohepatitis (NASH).